Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (a-TC1): Evidence of a direct effect of GLP-1 on pancreatic alpha cells

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Piro, Salvatore ^a   Mascali, Loriana G ^a   Urbano, Francesca ^a   Filippello, Agnese ^a   Malaguarnera, Roberta ^b   Calanna, Salvatore ^a   Rabuazzo, Agata M ^a   Purrello, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROPROTEIN CONVERTASE 1; TRANSCRIPTION FACTOR PAX6;

ANIMAL CELL; ARTICLE; CELL LEVEL; CONTROLLED STUDY; GCG GENE; GENE EXPRESSION; GLUCAGON RELEASE; HORMONE RELEASE; HORMONE SYNTHESIS; MALE; NONHUMAN; PANCREAS ISLET ALPHA CELL; PROTEIN EXPRESSION; RAT;

CELL LINE, TUMOR; CYCLIC AMP; EYE PROTEINS; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-SECRETING CELLS; HOMEODOMAIN PROTEINS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PAIRED BOX TRANSCRIPTION FACTORS; PROPROTEIN CONVERTASE 1; RECEPTORS, GLUCAGON; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 84896497879     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090093     Document Type: Article

References (65)

1. Ashcroft FM, Rorsman P (2012) Diabetes mellitus and the beta cell: the last ten years. Cell 148: 1160-1171.
2. Unger RH, Orci L (1975) The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1: 14-16.
3. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, et al. (2010) Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33: 428-433.
4. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157. (Pubitemid 46711096)
5. Ahren B (2007) GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Curr Diab Rep 7: 340-347. (Pubitemid 350200016)
6. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M (2002) The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45: 195-202. (Pubitemid 34208381)
7. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M (2009) Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 68: 898-905.
8. Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, Helleberg H, Larsen U, et al. (2010) Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 38: 1944-1953.
9. Dunning BE, Foley JE, Ahren B (2005) Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 48: 1700-1713. (Pubitemid 41317822)
10. Kedees MH, Grigoryan M, Guz Y, Teitelman G (2009) Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia. Mol Cell Endocrinol 311: 69-76.
11. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, et al. (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744. (Pubitemid 23218642)
12. de Heer J, Rasmussen C, Coy DH, Holst JJ (2008) Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51: 2263-2270.
13. Ding WG, Renstrom E, Rorsman P, Buschard K, Gromada J (1997) Glucagonlike peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 46: 792-800. (Pubitemid 27188256)
14. De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, et al. (2010) GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab 11: 543-553.
15. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, et al. (2012) A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55: 3262-3272.
16. Webb GC, Dey A, Wang J, Stein J, Milewski M, et al. (2004) Altered proglucagon processing in an alpha-cell line derived from prohormone convertase 2 null mouse islets. J Biol Chem 279: 31068-31075. (Pubitemid 39037767)
17. Hamaguchi K, Utsunomiya N, Takaki R, Yoshimatsu H, Sakata T (2003) Cellular interaction between mouse pancreatic alpha-cell and beta-cell lines: possible contact-dependent inhibition of insulin secretion. Exp Biol Med (Maywood) 228: 1227-1233. (Pubitemid 37413684)
18. Xiao J, Gregersen S, Kruhoffer M, Pedersen SB, Orntoft TF, et al. (2001) The effect of chronic exposure to fatty acids on gene expression in clonal insulinproducing cells: studies using high density oligonucleotide microarray. Endocrinology 142: 4777-4784. (Pubitemid 33022353)
19. Piro S, Maniscalchi ET, Monello A, Pandini G, Mascali LG, et al. (2010) Palmitate affects insulin receptor phosphorylation and intracellular insulin signal in a pancreatic alpha-cell line. Endocrinology 151: 4197-4206.
20. Chen L, Wang P, Andrade CF, Zhao IY, Dube PE, et al. (2005) PKA independent and cell type specific activation of the expression of caudal homeobox gene Cdx-2 by cyclic AMP. FEBS J 272: 2746-2759. (Pubitemid 40825422)
21. Fehmann HC, Janssen M, Goke B (1995) Interaction of glucagon-like peptide-I (GLP-I) and galanin in insulin (beta TC-1)- and somatostatin (RIN T3)-secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)-secreting cells. Acta Diabetol 32: 176-181.
22. Fehmann HC, Habener JF (1991) Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line. FEBS Lett 279: 335-340.
23. Drucker DJ, Campos R, Reynolds R, Stobie K, Brubaker PL (1991) The rat glucagon gene is regulated by a protein kinase A-dependent pathway in pancreatic islet cells. Endocrinology 128: 394-400.
24. Pipeleers DG, in't Veld PA, Van de Winkel M, Maes E, Schuit FC, et al. (1985) A new in vitro model for the study of pancreatic A and B cells. Endocrinology 117: 806-816. (Pubitemid 15019997)
25. Rasschaert J, Ladriere L, Urbain M, Dogusan Z, Katabua B, et al. (2005) Tolllike receptor 3 and STAT-1 contribute to double-stranded RNA+ interferongamma-induced apoptosis in primary pancreatic beta-cells. J Biol Chem 280: 33984-33991. (Pubitemid 41443119)
26. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, et al. (2003) Glucagonlike peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149-5158. (Pubitemid 37476040)
27. Kim SJ, Widenmaier SB, Choi WS, Nian C, Ao Z, et al. (2012) Pancreatic betacell prosurvival effects of the incretin hormones involve post-translational modification of Kv2.1 delayed rectifier channels. Cell Death Differ 19: 333-344.
28. Wang L, Guo F, Wei S, Zhao R (2011) Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes. Peptides 32: 1313-1319.
29. Tian G, Sandler S, Gylfe E, Tengholm A (2011) Glucose- and hormone-induced cAMP oscillations in alpha- and beta-cells within intact pancreatic islets. Diabetes 60: 1535-1543.
30. Barovsky K, Pedone C, Brooker G (1984) Distinct mechanisms of forskolinstimulated cyclic AMP accumulation and forskolin-potentiated hormone responses in C6-2B cells. Mol Pharmacol 25: 256-260. (Pubitemid 14173332)
31. Calanna S, Urbano F, Piro S, Zagami RM, Di Pino A, et al. (2012) Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in metabolic syndrome. Eur J Endocrinol 166: 917-922.
32. Calanna S, Piro S, Di Pino A, Maria Zagami R, Urbano F, et al. (2013) Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis. Obesity (Silver Spring) 21: 320-325.
33. Umezawa H, Aoyagi T, Ogawa K, Naganawa H, Hamada M, et al. (1984) Diprotins A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria. J Antibiot (Tokyo) 37: 422-425. (Pubitemid 14129498)
34. Reimann F, Gribble FM (2002) Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 51: 2757-2763. (Pubitemid 34970929)
35. Piro S, Spampinato D, Spadaro L, Oliveri CE, Purrello F, et al. (2008) Direct apoptotic effects of free fatty acids on human endothelial cells. Nutr Metab Cardiovasc Dis 18: 96-104. (Pubitemid 351291669)
36. Anello M, Spampinato D, Piro S, Purrello F, Rabuazzo AM (2004) Glucosamine-induced alterations of mitochondrial function in pancreatic betacells: possible role of protein glycosylation. Am J Physiol Endocrinol Metab 287: E602-608. (Pubitemid 39237886)
37. Rabuazzo AM, Patane G, Anello M, Piro S, Vigneri R, et al. (1997) Hexokinase shift to mitochondria is associated with an increased sensitivity to glucose in rat pancreatic islets. Diabetes 46: 1148-1152. (Pubitemid 27271075)
38. Malaguarnera R, Mandarino A, Mazzon E, Vella V, Gangemi P, et al. (2005) The p53-homologue p63 may promote thyroid cancer progression. Endocr Relat Cancer 12: 953-971. (Pubitemid 41815789)
39. Sengupta R, Sun T, Warrington NM, Rubin JB (2011) Treating brain tumors with PDE4 inhibitors. Trends Pharmacol Sci 32: 337-344.
40. Mikkola I, Bruun JA, Bjorkoy G, Holm T, Johansen T (1999) Phosphorylation of the transactivation domain of Pax6 by extracellular signal-regulated kinase and p38 mitogen-activated protein kinase. J Biol Chem 274: 15115-15126.
41. Prasadan K, Daume E, Preuett B, Spilde T, Bhatia A, et al. (2002) Glucagon is required for early insulin-positive differentiation in the developing mouse pancreas. Diabetes 51: 3229-3236. (Pubitemid 35246969)
42. St-Onge L, Sosa-Pineda B, Chowdhury K, Mansouri A, Gruss P (1997) Pax6 is required for differentiation of glucagon-producing alpha-cells in mouse pancreas. Nature 387: 406-409. (Pubitemid 27227205)
43. Ton CC, Hirvonen H, Miwa H, Weil MM, Monaghan P, et al. (1991) Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. Cell 67: 1059-1074. (Pubitemid 121001520)
44. Rouille Y, Kantengwa S, Irminger JC, Halban PA (1997) Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. J Biol Chem 272: 32810-32816. (Pubitemid 28023615)
45. Nie Y, Nakashima M, Brubaker PL, Li QL, Perfetti R, et al. (2000) Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J Clin Invest 105: 955-965. (Pubitemid 30203068)
46. Pyke C, Knudsen LB (2013) The Glucagon-Like Peptide-1 Receptor-or Not? Endocrinology 154: 4-8.
47. Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, et al. (2013) GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 154: 127-139.
48. Butler PC, Elashoff M, Elashoff R, Gale EA (2013) A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe? Diabetes Care.
49. Salehi A, Vieira E, Gylfe E (2006) Paradoxical stimulation of glucagon secretion by high glucose concentrations. Diabetes 55: 2318-2323. (Pubitemid 44743630)
50. Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28: 84-116. (Pubitemid 46220851)
51. Gosmain Y, Katz LS, Masson MH, Cheyssac C, Poisson C, et al. (2012) Pax6 is crucial for beta-cell function, insulin biosynthesis, and glucose-induced insulin secretion. Mol Endocrinol 26: 696-709.
52. Mojsov S, Kopczynski MG, Habener JF (1990) Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265: 8001-8008.
53. Heller RS, Aponte GW (1995) Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7-36) amide. Am J Physiol 269: G852-860.
54. Kreymann B, Ghatei MA, Domin J, Kanse S, Bloom SR (1991) Developmental patterns of glucagon-like peptide-1-(7-36) amide and peptide-YY in rat pancreas and gut. Endocrinology 129: 1001-1005.
55. Masur K, Tibaduiza EC, Chen C, Ligon B, Beinborn M (2005) Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining beta-cell function. Mol Endocrinol 19: 1373-1382. (Pubitemid 40594131)
56. Thyssen S, Arany E, Hill DJ (2006) Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. Endocrinology 147: 2346-2356.
57. Whalley NM, Pritchard LE, Smith DM, White A (2011) Processing of proglucagon to GLP-1 in pancreatic alpha-cells: is this a paracrine mechanism enabling GLP-1 to act on beta-cells? J Endocrinol 211: 99-106.
58. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, et al. (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17: 1481-1489.
59. Hansen AM, Bodvarsdottir TB, Nordestgaard DN, Heller RS, Gotfredsen CF, et al. (2011) Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus-an adaptive response to hyperglycaemia? Diabetologia 54: 1379-1387.
60. Tamagawa T, Ishiwata I, Sato K, Nakamura Y (2009) Induced in vitro differentiation of pancreatic-like cells from human amnion-derived fibroblast-like cells. Hum Cell 22: 55-63.
61. Larsson LI, St-Onge L, Hougaard DM, Sosa-Pineda B, Gruss P (1998) Pax 4 and 6 regulate gastrointestinal endocrine cell development. Mech Dev 79: 153-159. (Pubitemid 29038030)
62. Wideman RD, Yu IL, Webber TD, Verchere CB, Johnson JD, et al. (2006) Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc Natl Acad Sci U S A 103: 13468-13473. (Pubitemid 44380131)
63. Wideman RD, Covey SD, Webb GC, Drucker DJ, Kieffer TJ (2007) A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alphacells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice. Diabetes 56: 2744-2752. (Pubitemid 350044917)
64. Wideman RD, Gray SL, Covey SD, Webb GC, Kieffer TJ (2009) Transplantation of PC1/3-Expressing alpha-cells improves glucose handling and cold tolerance in leptin-resistant mice. Mol Ther 17: 191-198.
65. Leibiger B, Moede T, Muhandiramlage TP, Kaiser D, Vaca Sanchez P, et al. (2012) Glucagon regulates its own synthesis by autocrine signaling. Proc Natl Acad Sci U S A 109: 20925-20930.